BridgeBio Pharma (BBIO) After Its $2.21b Stock Filing Is It A Buy Or Priced In

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

Why BridgeBio Pharma Stock Is Back In Focus

BridgeBio Pharma (BBIO) is back on investor radars after filing two shelf registrations totaling about US$2.21b in common stock, alongside detailed updates on its late stage encaleret program for ADH1 and chronic hypoparathyroidism.

See our latest analysis for BridgeBio Pharma.

BridgeBio Pharma shares trade at US$80.09 after a recent 1 day share price return that declined 2.5%, although the 3 month share price return of 16.82% and 1 year total shareholder return of 69.07% still point to strong momentum around the encaleret NDA and fresh capital raising plans.

If the encaleret story has you looking across healthcare, this is a good moment to see what else is emerging in AI driven drug development and screening through 41 healthcare AI stocks

BridgeBio Pharma now trades around US$80 after a strong year and plans to issue up to about US$2.21b in new stock. Is this a moment to buy on momentum or wait for a potentially cheaper entry as dilution risks are priced in?

Most Popular Narrative: 220.4% Overvalued

BridgeBio Pharma last closed at $80.09, while the most followed narrative on Simply Wall St assigns a fair value of $25.00 per share, which implies a steep premium based on that framework.

The “BridgeBio Commercial Bonanza” is priced for perfection, treating the upcoming Acoramidis launch as an automatic cash cow while ignoring a brutal multi-front commercial dogfight.

Here is why the market is mispricing the structural hurdles for BBIO:

Read the complete narrative.

Want to see what sits behind that $25.00 figure? The narrative leans on ambitious revenue growth, rising margins and a rich future earnings multiple. Curious which projections really move the fair value?

Result: Fair Value of $25.00 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, BridgeBio Pharma could surprise narrative skeptics if encaleret data impresses regulators or if commercial execution costs turn out to be lower than feared.

Find out about the key risks to this BridgeBio Pharma narrative.

Another View On BridgeBio Pharma’s Valuation

That $25.00 narrative fair value is one lens. Our DCF model takes a very different view, suggesting BridgeBio Pharma at $80.09 is trading at a 74.7% discount to an estimated future cash flow value of $316.46. Which story better fits how you think about risk?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out BridgeBio Pharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

With BridgeBio Pharma drawing mixed reactions from different valuation models, it makes sense to move quickly and weigh the trade off between concerns and optimism yourself through the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond BridgeBio Pharma?

If BridgeBio Pharma has sharpened your focus, do not stop here. The Simply Wall Street screener can help you quickly spot other opportunities that match your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BBIO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com